Provide optimized antidepressant monotherapy with multiple drugs before considering antidepressant polypharmacy.
Combining antidepressants may be useful in some special cases, but there is little evidence to support making this a standard approach for managing treatment-resistant depression. The potential benefits of antidepressant polypharmacy include potentiation of the partial effectiveness of the initial monotherapy regimen, particularly in resistant depressive cases that show limited benefit from multiple monotherapy switch treatments. Most of the benefit of this type of polypharmacy occurs in individuals with unipolar depression. Various risks of antidepressant polypharmacy include: (a) drug-drug interactions and the impact on medication metabolism; (b) the potential for increased adverse effects, increased rates of treatment-emergent mania, or cycling of bipolar affective patients; (c) increased financial burden; and (d) increased risk of patients' medication errors.
Despite the absence of robust evidence, antidepressant polypharmacy has become commonplace among psychiatrists in high-income countries, particularly among patients classified as 'treatment-resistant' due to failure of multiple monotherapy trials. In a study of office-based psychiatric practices between 1996 and 2006 based on the National Ambulatory Medical Care Survey,  polypharmacy with two or more antidepressants was disproportionately more common among adults 45 to 64 years of age versus those 18 to 44, and it was significantly more common in women than in men. In a separate chart review of 135 patients,  antidepressant polypharmacy was no better than antidepressant monotherapy in terms of medication response (based on changes in the Clinical Global Impressions Scale (CGI) score), clinical response, or remission rates. This paper also reported that many of the monotherapy trials patients had received prior to 'graduating' to antidepressant polypharmacy were inadequate either in dose or duration. This lends to the concern that general psychiatric practitioners may initiate polypharmacy prematurely, before the effectiveness of monotherapy is fully tested.
The combination of mirtazapine and venlafaxine--termed 'California rocket fuel'--was widely publicized as an effective regimen for treatment-resistant depression. A little over a decade ago, this set off a popular trend among clinicians of utilizing multiple adjunct antidepressants to treat recurrent and severe depression. However, data from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study  did not find significantly increased remission rates of patients taking the mirtazapine plus venlafaxine combination versus those on monotherapy with tranylcypromine. However, the side effect profiles and overall tolerability were more favorable with the combination regimen than when using a monoamine oxidase inhibitor. The more recent large-scale Combining Medications to Enhance Depression Outcomes (COMED) study  again failed to show that antidepressant polypharmacy was superior to antidepressant monotherapy.
The prevalence of antidepressant use among adults in the community in the United States has increased 3-to 4-fold over the last 15 years, reaching an astounding 8-10% of the adult population by 2010.  Despite the lack of evidence of effectiveness of antidepressant polypharmacy, as part of this general increase in the use of antidepressants, antidepressant polypharmacy has also increased. Healthplan database reviews in 2011 found that antidepressant polypharmacy was present in 2% of 1615 older adults participating in the health plan and in 3% of 4854 younger adults. 
Although it is a widely-used practice among psychiatrists and primary care physicians in high-income countries, given the very limited evidence of effectiveness, care should be taken to limit use of antidepressant polypharmacy approaches to the very small number of cases that have failed optimized monotherapy with a variety of antidepressants from different classes. For patients who continue to demonstrate treatment resistance after multiple adequate monotherapy trials, alternative treatment modalities should probably be considered before resorting to antidepressant polypharmacy. These alternative approaches include electroconvulsive therapy (ECT), transcranial magnetic stimulation (rTMS), and ketamine, all of which--unlike antidepressant polypharmacy--have shown efficacy in treatment-resistant patients. These alternative treatments have very different mechanisms of action so, unlike antidepressant polypharmacy, they may be able to overcome treatment resistance that develops to conventional antidepressant agents.
Conflict of Interest
The authors report no conflict of interest related to this manuscript.
No funding was received for preparing this commentary.
[1.] Shelton RC, Osuntokun O, Heinloth AN, Corya SA. Therapeutic options for treatment-resistant depression. CNS drugs. 2010; 24(2): 131-161. Epub 2010 Jan 22. doi: http://dx.doi.org/10.2165/11530280-000000000-00000
[2.] Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010; 67(1): 26-36. Epub 2010 Jan 06. doi: http://dx.doi.org/10.1001/archgenpsychiatry.2009.175
[3.] Glezer A, Byatt N, Cook R, Jr., Rothschild AJ. Polypharmacy prevalence rates in the treatment of unipolar depression in an outpatient clinic. J Affect Disorders. 2009; 117(1-2): 18-23. Epub 2008 Dec 24. doi: http://dx.doi.org/10.1016/j.jad.2008.11.016
[4.] McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006; 163(9): 1531-1541. Epub 2006 Sep 02
[5.] Cooper C, Katona C, Lyketsos K, Blazer D, Brodaty H, Rabins P, et al. A systematic review of treatments for refractory depression in older people. Am J Psychiatry. 2011; 168(7): 681-8. Epub 2011 Apr 02
[6.] Warden D, Trivedi MH, Carmody T, Toups M, Zisook S, Lesser I, et. al. Adherence to antidepressant combinations and monotherapy for major depressive disorder: a COMED report of measurement-based care. J Psychiatr Pract. 2014; 20(2): 118-132. Epub 2014 Mar 19. doi: http://dx.doi. org/10.1097/01.pra.0000445246.46424.fe
[7.] Milea D, Verpillat P, Guelfucci F, Toumi M, Lamure M. Prescription patterns of antidepressants: findings from a US claims database. Curr Med Res Opin. 2010; 26(6): 1343-53. Epub 2010 Apr 09. doi: http://dx.doi. org/10.1185/03007991003772096
[8.] Sanglier T, Saragoussi D, Milea D, Auray JP, Valuck RJ, Tournier M. Comparing antidepressant treatment patterns in older and younger adults: a claims database analysis. J Am Geriatr Soc. 2011; 59(7): 1197-1205. Epub 2011 Jul 02. doi: http://dx.doi.org/10.1111/j.1532-5415.2011.03457.x (received, 2014-12-05; accepted, 2014-12-12)
Tammy Saah, MD, is a senior associate and the first Treatment Resistant Depression Fellow in the Department of Psychiatry and Behavioral Sciences at Emory University. Dr. Saah is involved in the development of the Treatment Resistant Depression (TRD) Clinic at Emory and a supervisor in the department's Dialectical Behavior Therapy group. Dr. Saah's clinical and research interests are focused in TRD, with an emphasis on advanced psychopharmacology, novel therapeutics, and ne uromodulation.
Tammy SAAH *, Steven J. GARLOW, Mark H. RAPAPORT
Department of Psychiatry and Behavioral Sciences, Emory University, Georgia, United States
* correspondence: firstname.lastname@example.org
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Forum: Antidepressant polypharmacy|
|Author:||Saah, Tammy; Garlow, Steven J.; Rapaport, Mark H.|
|Publication:||Shanghai Archives of Psychiatry|
|Date:||Dec 1, 2014|
|Previous Article:||When is antidepressant polypharmacy appropriate in the treatment of depression?|
|Next Article:||Combining antidepressants.|